Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Eur Rev Med Pharmacol Sci ; 28(9): 3455-3462, 2024 May.
Article in English | MEDLINE | ID: mdl-38766798

ABSTRACT

OBJECTIVE: Our study aims to determine the frequency and types of GTD (Gestational Trophoblastic Disease) in our clinic, to evaluate its relationship with clinical parameters, and the consistency of clinical prediagnosis and pathological definitive diagnosis. PATIENTS AND METHODS: In the present study, hospital records of 120 patients with gestational trophoblastic disease between January 2019 and August 2022 were obtained and evaluated retrospectively. Demographic, hematological, biochemical, and clinical data were collected in detail, and the data were analyzed statistically. RESULTS: Our study included a total of 120 female patients, with an average age of 31.16±9.70. The average number of patients was 3. The average time for women to receive the diagnosis was 9.80±2.45 weeks, with the most frequent complaint on our part being bleeding (85.8%). When the pathology outcomes of the patients we included in our study were examined, it was found that the number of patients diagnosed with incomplete abortion was 34, the number of patients diagnosed with complete abortion was 82, the number of invasive moles diagnosed was 3, and the number of patient diagnosed with choriocarcinoma was 1. Kappa ratio was calculated as 0.419 (p<0.001) when the compliance of the clinical diagnosis was assessed. This value was consistent with median level alignment. In a study that examined the three years of our calism in our bulk, 1.8 per 1,000 births were followed frequently. CONCLUSIONS: We should inform patients in detail about gestational trophoblastic diseases and warn patients not to delay their consequences. We should recommend that pregnancy be avoided for 12 months for low-risk patients and 18 months for high-risk patients after GTD.


Subject(s)
Gestational Trophoblastic Disease , Humans , Female , Gestational Trophoblastic Disease/diagnostic imaging , Gestational Trophoblastic Disease/diagnosis , Pregnancy , Retrospective Studies , Adult , Young Adult
2.
Arch Gynecol Obstet ; 266(3): 141-4, 2002 Jul.
Article in English | MEDLINE | ID: mdl-12197552

ABSTRACT

The purpose of this study was to evaluate the efficacy of methyldopa in the treatment of preeclamptic patients. This study was performed on 24 preeclamptic women who were in between 25-36 weeks of gestational age. 24 healthy pregnant women were taken as control group. Before starting treatment, 24 preeclamptic patients were examined with Doppler ultrasound. Pulsatility index, resistance index, systolic/diastolic ratio of uterine, umblical and fetal middle cerebral arteries were measured. Preeclamptic patients were treated with totally 1 g methyldopa per day. After 7 d, patients were reexamined with Doppler ultrasound. The effect of methyldopa on uterine, umblical and fetal middle cerebral artery blood flows were detected. Only one control with Doppler ultrasound was done to the healthy pregnant women. Before methyldopa treatment to the preeclamptic women, pulsatility index (PI), resistance index (RI) and systolic/diastolic ratio (S/D) on uterine and umblical arteries were significantly higher than the control group. However, fetal middle cerebral artery (MCA) values were significantly lower than the control group. When Doppler results of preeclamptic patients before and after the methyldopa treatment were compared, no significant differences in terms of Pulsatility Index, Resistance IndexI and S/D ratio of umblical and fetal middle cerebral arteries were found. However, the results of uterine artery were significantly lower after the treatment in preeclamptic patients. Treatment with methyldopa lowered the uterine artery resistance in preeclamptic patients but did not effect the resistance of umblical and fetal middle cerebral artery.


Subject(s)
Antihypertensive Agents/pharmacology , Fetus/blood supply , Hemodynamics/drug effects , Methyldopa/pharmacology , Placental Circulation/drug effects , Pre-Eclampsia/drug therapy , Adult , Antihypertensive Agents/therapeutic use , Blood Flow Velocity , Female , Fetus/drug effects , Humans , Methyldopa/therapeutic use , Middle Cerebral Artery/diagnostic imaging , Middle Cerebral Artery/drug effects , Middle Cerebral Artery/physiopathology , Placenta/blood supply , Placenta/diagnostic imaging , Placenta/drug effects , Pre-Eclampsia/diagnostic imaging , Pre-Eclampsia/physiopathology , Pregnancy , Ultrasonography, Doppler , Ultrasonography, Prenatal , Umbilical Arteries/diagnostic imaging , Umbilical Arteries/drug effects , Umbilical Arteries/physiopathology , Uterus/blood supply , Uterus/diagnostic imaging , Uterus/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL